Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to -$276.9 million.

  • Pharming's Retained Earnings rose 53.63% to -$276.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$276.9 million, marking a year-over-year increase of 53.63%. This contributed to the annual value of -$275.5 million for FY2024, which is 385.54% down from last year.
  • Per Pharming's latest filing, its Retained Earnings stood at -$276.9 million for Q3 2025, which was up 53.63% from -$286.0 million recorded in Q2 2025.
  • In the past 5 years, Pharming's Retained Earnings ranged from a high of -$242533.0 in Q3 2022 and a low of -$292.8 million during Q1 2025
  • For the 5-year period, Pharming's Retained Earnings averaged around -$216.6 million, with its median value being -$270.5 million (2022).
  • Its Retained Earnings has fluctuated over the past 5 years, first surged by 9991.25% in 2022, then tumbled by 10824649.31% in 2023.
  • Pharming's Retained Earnings (Quarter) stood at -$272243.4 in 2021, then plummeted by 3109.26% to -$8.7 million in 2022, then plummeted by 2936.08% to -$265.3 million in 2023, then decreased by 3.86% to -$275.5 million in 2024, then dropped by 0.5% to -$276.9 million in 2025.
  • Its Retained Earnings stands at -$276.9 million for Q3 2025, versus -$286.0 million for Q2 2025 and -$292.8 million for Q1 2025.